Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Congenital Bleeding Disorder clinical trials
Every US clinical trial registered for Congenital Bleeding Disorder — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
9 US clinical trials ·
The research picture
Congenital Bleeding Disorder has 9 registered US clinical trials; none are currently listed as recruiting, so most are completed or in follow-up.
- 0
- recruiting participants now
- 0%
- of trials open to enrollment
- 6
- in Phase 3–4 (later-stage)
- 9
- top sponsor: Novo Nordisk A/S
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
Novo Nordisk A/S
NCT02568202
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Novo Nordisk A/S
NCT00984126
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
Novo Nordisk A/S
NCT01480180
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Novo Nordisk A/S
NCT01392547
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Novo Nordisk A/S
NCT01138501
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Novo Nordisk A/S
NCT02141074
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
Novo Nordisk A/S
NCT01467427
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Novo Nordisk A/S
NCT02490787
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Novo Nordisk A/S
NCT00108758
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 6 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Congenital Bleeding Disorder Trial Landscape
ClinicalTrials.gov lists 9 US studies indexed under Congenital Bleeding Disorder, and 0 of those are currently open to recruitment — roughly 0% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Congenital Bleeding Disorder shows 6 late-stage studies (Phase 3 and Phase 4 combined) alongside 2 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Congenital Bleeding Disorder is led by Novo Nordisk A/S with 9 indexed trials, alongside 0 other organizations in the top contributor list. The list on this page surfaces up to 9 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Congenital Bleeding Disorder?
PlainTrial tracks 9 US clinical trials for Congenital Bleeding Disorder, of which 0 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Congenital Bleeding Disorder?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.